{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:26:48Z","timestamp":1777418808086,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2010,12,21]],"date-time":"2010-12-21T00:00:00Z","timestamp":1292889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:p>Medical abortion is increasingly heralded as an ideal method for decreasing maternal mortality in health-care resource-deprived areas and as an answer to the shrinking pool of physicians willing to perform abortions. The advent of progesterone receptor modulators (PRMs) and the recent approval by the Food and Drug Administration of ella (ulipristal) as an emergency contraceptive put pharmacists in the center of abortion controversy. Pharmacists, worldwide, need to be aware of the controversy surrounding the introduction of PRMs. particularly with regard to the effect on health policy, their mechanism of action, associated adverse events, and common off-label uses. Once understood, genuine opportunity exists for pharmacists to serve a fundamental role in positively shaping public health policy.<\/jats:p>","DOI":"10.1345\/aph.1p608","type":"journal-article","created":{"date-parts":[[2010,12,21]],"date-time":"2010-12-21T23:17:29Z","timestamp":1292973449000},"page":"115-119","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Defining Reality: The Potential Role of Pharmacists in Assessing the Impact of Progesterone Receptor Modulators and Misoprostol in Reproductive Health"],"prefix":"10.1177","volume":"45","author":[{"given":"Donna J","family":"Harrison","sequence":"first","affiliation":[{"name":"American Association of ProLife Obstetricians and Gynecologists, Holland, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James G","family":"Mitroka","sequence":"additional","affiliation":[{"name":"Lloyd L Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2010,12,21]]},"reference":[{"key":"bibr1-aph.1P608","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2005.02.008"},{"key":"bibr2-aph.1P608","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2003.12.004"},{"key":"bibr3-aph.1P608","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199804303381801"},{"key":"bibr4-aph.1P608","unstructured":"Food and Drug Administration. Mifeprex label, www.accessdata.fda.gov\/drugsatfda_docs\/label\/2000\/206871bl.htm (accessed 2010 Sept 26)."},{"key":"bibr5-aph.1P608","author":"American Association of Pro Life Obstetricians and Gynecologists, Christian Medical Association and Concerned Women for America.","year":"2002","journal-title":"Filed FDA"},{"key":"bibr6-aph.1P608","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G481"},{"key":"bibr7-aph.1P608","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051620"},{"key":"bibr8-aph.1P608","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G189"},{"key":"bibr9-aph.1P608","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K351"},{"key":"bibr10-aph.1P608","unstructured":"European Medicines Agency. CHMP assessment report for EllaOne. (Doc.Ref.: EMEA\/261787\/2009). London, UK. www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_Public_assessment_report\/human\/001027\/WC500023673.pdf (accessed 2010 Dec 9)."},{"key":"bibr11-aph.1P608","unstructured":"European Medicines Agency, Product Information Annex I (19\/03\/2010 Ellaone-H-C-1027-IA-04) (updated May 7,2010): sec. 53, p2. www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001027\/WC500023670.pdf (accessed 2010 Sept 25)."},{"key":"bibr12-aph.1P608","unstructured":"ICH M3 (R2): Guideline on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals (current Step 4 ver. June 11, 2009): sec. 11.3 (\u201cWomen of Childbearing Potential\u201d). www.fda.gov\/RegulatoryInformation\/Guidances\/ucm129520.htm (accessed 2010 Sept 25)."},{"key":"bibr13-aph.1P608","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/9.suppl_1.12"},{"key":"bibr14-aph.1P608","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(96)00134-5"},{"key":"bibr15-aph.1P608","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181c8e2aa"},{"key":"bibr16-aph.1P608","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60101-8"},{"key":"bibr17-aph.1P608","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000239440.02284.45"},{"key":"bibr18-aph.1P608","volume-title":"Medical officer's addendum. Study #9728: Plan B OTC label comprehension study. sNDA-21\u2013045","author":"Food and Drug Administration."},{"key":"bibr19-aph.1P608","volume-title":"Guidance for industry format and content of proposed risk evaluation and mitigation strategies (REMS), REMS assessments, and proposed REMS modifications","author":"Food and Drug Administration.","year":"2010"},{"key":"bibr20-aph.1P608","unstructured":"ICD9Data.com.www.icd9data.com\/2010\/Volumel\/630-679\/630-639\/635\/default.htm (accessed 2010 Dec 9)."},{"key":"bibr21-aph.1P608","unstructured":"Food and Drug Administration. Risk evaluation and mitigation strategy (REMS), the iPLEDGE program single shared system for isotretinoin. www.accessdata.fda.gov\/drugsatfda_docs\/labeI\/2010\/018662s061REMS.pdf (accessed 2010 Oct 30)."},{"key":"bibr22-aph.1P608","author":"World Health Organization.","year":"2007","journal-title":"National-level monitoring of the achievement of universal access to reproductive health: conceptual and practical considerations and related indicators\u2014report of a WHO\/UNFPA technical consultation"},{"key":"bibr23-aph.1P608","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61575-X"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1P608","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1P608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:08:01Z","timestamp":1777374481000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1P608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,21]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1345\/aph.1P608"],"URL":"https:\/\/doi.org\/10.1345\/aph.1p608","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,21]]}}}